Apellis Pharmaceuticals (APLS) News Today → Millionaire Investor makes surprising election prediction (From InvestorPlace) (Ad) Free APLS Stock Alerts $41.31 -0.69 (-1.64%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 18 at 2:18 PM | marketbeat.comGreat Lakes Advisors LLC Invests $12.46 Million in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Great Lakes Advisors LLC purchased a new stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 208,163 shares of the company's stock, valued at approximately $12,461,000. Great Lakes AdvisMay 18 at 2:17 AM | americanbankingnews.comBrokers Set Expectations for Apellis Pharmaceuticals, Inc.'s Q2 2024 Earnings (NASDAQ:APLS)May 17 at 7:50 AM | marketbeat.comApellis Pharmaceuticals, Inc. Forecasted to Earn Q2 2024 Earnings of ($0.41) Per Share (NASDAQ:APLS)Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Research analysts at Wedbush upped their Q2 2024 earnings per share (EPS) estimates for Apellis Pharmaceuticals in a report issued on Wednesday, May 15th. Wedbush analyst L. Chico now anticipates that the company will post earnings of ($May 17 at 6:20 AM | marketbeat.comBNP Paribas Financial Markets Sells 68,867 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)BNP Paribas Financial Markets decreased its stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 29.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 167,488 shares of the company's stock after selling 68,867 shares durinMay 17 at 5:28 AM | americanbankingnews.comEquities Analysts Offer Predictions for Apellis Pharmaceuticals, Inc.'s Q2 2025 Earnings (NASDAQ:APLS)May 17 at 1:30 AM | americanbankingnews.comApellis Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:APLS)May 16 at 3:38 PM | marketbeat.comInvestors Buy High Volume of Call Options on Apellis Pharmaceuticals (NASDAQ:APLS)Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Get Free Report) saw some unusual options trading on Thursday. Investors purchased 40,472 call options on the company. This is an increase of 1,641% compared to the typical daily volume of 2,325 call options.May 16 at 9:16 AM | marketbeat.comWedbush Comments on Apellis Pharmaceuticals, Inc.'s Q2 2025 Earnings (NASDAQ:APLS)Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Equities research analysts at Wedbush issued their Q2 2025 earnings per share estimates for shares of Apellis Pharmaceuticals in a research note issued to investors on Wednesday, May 15th. Wedbush analyst L. Chico expects that the companMay 16 at 7:02 AM | americanbankingnews.comApellis Pharmaceuticals, Inc. (NASDAQ:APLS) Sees Significant Increase in Short InterestMay 14, 2024 | marketbeat.comApellis Pharmaceuticals (NASDAQ:APLS) Trading Down 4%Apellis Pharmaceuticals (NASDAQ:APLS) Shares Down 4%May 14, 2024 | marketbeat.comShort Interest in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Expands By 16.1%Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Get Free Report) was the recipient of a large increase in short interest in April. As of April 30th, there was short interest totalling 12,390,000 shares, an increase of 16.1% from the April 15th total of 10,670,000 shares. Based on an average trading volume of 1,470,000 shares, the days-to-cover ratio is presently 8.4 days.May 14, 2024 | finance.yahoo.comApellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facility from Sixth StreetMay 13, 2024 | seekingalpha.comApellis Pharmaceuticals Strives For Recovery Despite Syfovre SetbacksMay 13, 2024 | americanbankingnews.comBrokers Offer Predictions for Apellis Pharmaceuticals, Inc.'s Q2 2024 Earnings (NASDAQ:APLS)May 12, 2024 | americanbankingnews.comApellis Pharmaceuticals, Inc. (NASDAQ:APLS) to Post FY2025 Earnings of $0.24 Per Share, HC Wainwright ForecastsMay 11, 2024 | insidertrades.comPascal Deschatelets Sells 78,907 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) StockMay 11, 2024 | americanbankingnews.comQ2 2024 EPS Estimates for Apellis Pharmaceuticals, Inc. Raised by Wedbush (NASDAQ:APLS)May 10, 2024 | markets.businessinsider.comStrong Performance and Growth Potential Affirm Buy Rating for Apellis PharmaceuticalsMay 10, 2024 | marketbeat.comHC Wainwright Weighs in on Apellis Pharmaceuticals, Inc.'s FY2025 Earnings (NASDAQ:APLS)Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Equities researchers at HC Wainwright boosted their FY2025 earnings per share (EPS) estimates for shares of Apellis Pharmaceuticals in a note issued to investors on Wednesday, May 8th. HC Wainwright analyst D. Tsao now expects that the cMay 10, 2024 | americanbankingnews.comBrokers Offer Predictions for Apellis Pharmaceuticals, Inc.'s FY2026 Earnings (NASDAQ:APLS)May 10, 2024 | americanbankingnews.comApellis Pharmaceuticals, Inc. (NASDAQ:APLS) Given Consensus Rating of "Moderate Buy" by BrokeragesMay 10, 2024 | americanbankingnews.comHC Wainwright Reiterates "Buy" Rating for Apellis Pharmaceuticals (NASDAQ:APLS)May 10, 2024 | americanbankingnews.comApellis Pharmaceuticals (NASDAQ:APLS) Stock Rating Reaffirmed by Needham & Company LLCMay 10, 2024 | americanbankingnews.comApellis Pharmaceuticals (NASDAQ:APLS) PT Lowered to $85.00May 10, 2024 | americanbankingnews.comApellis Pharmaceuticals (NASDAQ:APLS) PT Lowered to $60.00May 9, 2024 | marketbeat.comWedbush Analysts Reduce Earnings Estimates for Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Investment analysts at Wedbush lowered their FY2026 earnings per share estimates for shares of Apellis Pharmaceuticals in a research report issued to clients and investors on Tuesday, May 7th. Wedbush analyst L. Chico now expects that thMay 8, 2024 | markets.businessinsider.comApellis Pharmaceuticals Holds Steady Amid Market Challenges and Competitive PressuresMay 8, 2024 | msn.comApellis stock sell-off over Syfovre sales "overdone," says CitiMay 8, 2024 | markets.businessinsider.comIn-Depth Examination Of 14 Analyst Recommendations For Apellis PharmaceuticalsMay 8, 2024 | marketbeat.comApellis Pharmaceuticals (NASDAQ:APLS) Given New $60.00 Price Target at CitigroupCitigroup dropped their price target on Apellis Pharmaceuticals from $67.00 to $60.00 and set a "buy" rating on the stock in a research report on Wednesday.May 8, 2024 | marketbeat.comApellis Pharmaceuticals' (APLS) Buy Rating Reaffirmed at HC WainwrightHC Wainwright restated a "buy" rating and set a $92.00 price objective on shares of Apellis Pharmaceuticals in a research report on Wednesday.May 8, 2024 | marketbeat.comApellis Pharmaceuticals (NASDAQ:APLS) Issues Quarterly Earnings Results, Meets EstimatesApellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) issued its quarterly earnings results on Tuesday. The company reported ($0.54) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.54). The company had revenue of $172.33 million for the quarter, compared to analyst estimates of $163.37 million. Apellis Pharmaceuticals had a negative return on equity of 178.60% and a negative net margin of 133.34%. The business's revenue for the quarter was up 284.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($1.56) EPS.May 8, 2024 | finance.yahoo.comApellis Pharmaceuticals First Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsMay 7, 2024 | finanznachrichten.deApellis Pharmaceuticals, Inc.: Apellis Pharmaceuticals Reports First Quarter 2024 Financial ResultsMay 7, 2024 | msn.comAPLS Stock Earnings: Apellis Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024May 7, 2024 | seekingalpha.comApellis Pharmaceuticals, Inc. 2024 Q1 - Results - Earnings Call PresentationMay 7, 2024 | marketbeat.comApellis Pharmaceuticals (NASDAQ:APLS) Shares Gap Down to $48.81Apellis Pharmaceuticals (NASDAQ:APLS) Shares Gap Down to $48.81May 7, 2024 | msn.comApellis Pharmaceuticals GAAP EPS of -$0.54 misses by $0.09, revenue of $172.3M beats by $8.04MMay 7, 2024 | globenewswire.comApellis Pharmaceuticals Reports First Quarter 2024 Financial ResultsMay 7, 2024 | marketbeat.comVictory Capital Management Inc. Has $36.89 Million Stock Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Victory Capital Management Inc. lessened its stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 16.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 616,272 shares of theMay 6, 2024 | marketbeat.comApellis Pharmaceuticals, Inc. (NASDAQ:APLS) Holdings Decreased by Lisanti Capital Growth LLCLisanti Capital Growth LLC trimmed its position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 58.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 46,305 shares of the company's stock after selling 64,695May 6, 2024 | globenewswire.comApellis Pharmaceuticals to Host a Fireside Chat at the Bank of America Securities Healthcare ConferenceMay 3, 2024 | marketbeat.comCalifornia Public Employees Retirement System Sells 38,011 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)California Public Employees Retirement System reduced its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 20.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 145,833 shares of the company'sMay 1, 2024 | globenewswire.comApellis Announces 11 Oral Presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual MeetingApril 30, 2024 | marketbeat.comApellis Pharmaceuticals (NASDAQ:APLS) Sees Strong Trading VolumeApellis Pharmaceuticals (NASDAQ:APLS) Sees Large Volume IncreaseApril 30, 2024 | marketbeat.comApellis Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:APLS)Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Get Free Report) was the target of some unusual options trading activity on Tuesday. Stock investors purchased 18,182 call options on the company. This represents an increase of approximately 703% compared to the typical volume of 2,265 call options.April 30, 2024 | investing.comApellis Pharmaceuticals stock falls following Mizuho comments, price target cutApril 30, 2024 | benzinga.comA Closer Look at Apellis Pharmaceuticals's Options Market DynamicsApril 30, 2024 | marketbeat.comApellis Pharmaceuticals (APLS) Set to Announce Quarterly Earnings on TuesdayApellis Pharmaceuticals (NASDAQ:APLS) will be releasing earnings before the market opens on Tuesday, May 7, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=587617)April 29, 2024 | marketbeat.comApellis Pharmaceuticals (NASDAQ:APLS) Trading Down 3.5% After Analyst DowngradeApellis Pharmaceuticals (NASDAQ:APLS) Stock Price Down 3.5% Following Analyst Downgrade Get Apellis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for APLS and its competitors with MarketBeat's FREE daily newsletter. Email Address Breaking News: Elon Musk Invents New Type of A.I. (Shocking) (Ad)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street veteran, Eric Fry… This mind-blowing new technology could be bigger than the iPhone. Click here for the full story… APLS Media Mentions By Week APLS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. APLS News Sentiment▼0.910.49▲Average Medical News Sentiment APLS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. APLS Articles This Week▼258▲APLS Articles Average Week Get Apellis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for APLS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: BBIO News OGN News IONS News MDGL News ALPN News NUVL News CYTK News ALKS News PRGO News BPMC News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:APLS) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingHe called Apple at $1.49 and now he says: “Buy these 6 AI stocks.”InvestorPlaceThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaWhat’s Really Next for America…Porter & Company[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsA letter is coming from the "Bureau of the Fiscal Service".Stansberry ResearchClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apellis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
